Evidence map›Paper›PMID 41440197›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Canadian Prostate Cancer Trends in the Context of PSA Screening Guideline Changes.

Anna N Wilkinson, Larry F Ellison, Shary X Zhang, Michael Ong, Scott C Morgan, S Larry Goldenberg, Rodney H Breau, Christopher Morash

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna N WilkinsonDepartment of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0002-5422-8428
Larry F EllisonCentre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, ON K1A 0T6, Canada.ORCID 0000-0002-7284-6780
Shary X ZhangCentre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, ON K1A 0T6, Canada.
Michael OngDivision of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0002-0347-5541
Scott C MorganDivision of Radiation Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0002-6568-3346
S Larry GoldenbergDepartment of Urologic Sciences and the Vancouver Prostate Centre, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Rodney H BreauDivision of Urology, Department of Surgery, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Christopher MorashDivision of Urology, Department of Surgery, University of Ottawa, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0003-1363-8137

Funding

Prostate Cancer Foundation Canada 0Sullivan Urology Foundation 0
6 · The paper itself

Abstract

Prostate cancer is the most diagnosed cancer among Canadian men, except non-melanoma skin cancers. Prostate-specific antigen (PSA) screening can enable early detection, but it is not formally recommended in Canada. Nonetheless, opportunistic screening persists, influenced by US practices and some Canadian guidelines that support screening. This study provides a detailed analysis of trends in prostate cancer incidence, mortality, stage distribution, and net survival in the context of evolving PSA screening guidelines. Prostate cancer case (1984-2022) and death (1984-2023) data were primarily from the Canadian Cancer Registry and the Canadian Vital Statistics Death database, respectively. Joinpoint regression identified incidence and mortality trends. Net survival was determined using the Pohar Perme estimator. Following the introduction of PSA screening, the prostate cancer age-standardized incidence rate among men aged 50-74 increased 1.8% annually until 2007 (

Indexed as

Early Detection of CancerProstate-Specific AntigenProstatic NeoplasmsAgedCanadaHumansIncidenceMaleMass ScreeningMiddle AgedPractice Guidelines as TopicProstate-Specific Antigencancer registrymortalityprostate cancerPSAscreeningstagesurvival

Identifiers

PMID41440197
PMCPMC12731625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.